Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,019 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07135128RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
Jinan, ShandongAges 18 years+ - NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT06307925RecruitingPhase 1
HC010 for advanced solid tumors: a safety and early efficacy study
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT07100249RecruitingPhase 1
Study of HDM2012 for advanced solid tumors
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
ShanghaiAges 18–75 - NCT07077434RecruitingPhase 1
Study of Navlimetostat for advanced solid tumors with specific gene change
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07083323RecruitingPhase 1/Phase 2
Study of HY05350 for mesothelin-positive advanced solid tumors
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07067567RecruitingPhase 1
Study of AK146D1 injection for advanced solid tumors
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07019779RecruitingPhase 1/Phase 2
Study of CM518D1 for advanced solid tumors
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
Guangzhou, GuangdongAges 18–75 - NCT07004296RecruitingPhase 1
Study of HDM2005 for advanced solid tumors
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Guangzhou, GuangdongAges 18 years+ - NCT06992713RecruitingPhase 1
Study of H1710 for advanced solid tumors
This trial tests a new drug called H1710 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if H1710 is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06938880RecruitingPhase 1/Phase 2
ZGGS18 plus ZG005 for advanced solid tumors
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06927570RecruitingPhase 1
Study of HS-20122 for advanced solid tumors
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06929663RecruitingPhase 1
Study of AK146D1 for advanced solid tumors
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Sydney, New South WalesAges 18–75 - NCT06882135RecruitingPhase 1
Testing an experimental drug for advanced solid tumors
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06888830RecruitingPhase 1/Phase 2
Study of JS212 for advanced solid tumors
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT05881525RecruitingPhase 1
Testing NY-ESO-1 T-cell therapy for advanced solid tumors
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
ChongqingAges 18–70 - NCT06804824RecruitingPhase 1
Testing a new drug for advanced solid tumors with certain gene changes
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Grand Rapids, MichiganAges 18 years+ - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
San Diego, CaliforniaAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,019 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.